Trial Profile

A Phase I Study of the Safety, Tolerability and Immune Effects of the Nasal Anti-CD3 Monoclonal Antibody Foralumab in Healthy Human Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Foralumab (Primary)
Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Crohn's disease; Haemorrhage; Multiple sclerosis; Neurodegenerative disorders; Obesity; Post acute COVID 19 syndrome; Traumatic brain injuries; Type 1 diabetes mellitus
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Tiziana Life Sciences

Most Recent Events

23 Nov 2022 According to a Tiziana Life Sciences media release, data from this study published in Frontiers in Immunology
23 Nov 2022 Results published in the Tiziana Life Sciences Media Release
26 May 2021 Results published in the Tiziana Life Sciences Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com